In one study of 12 B-ALL patients who relapsed after anti-CD19 CAR-T therapy, each patient had a unique insertion or deletion in the CD19 gene (most frequently affecting exons 2–5). The gene discussed is CD19; the disease is acute lymphoblastic leukemia.